Abstract
Antimicrobial resistance (AMR) is a serious public health threat. Neisseria gonorrhoeae has developed resistance to all antibiotics recommended for treatment and reports of reduced susceptibility to ceftriaxone, the last-line treatment, are increasing. Since many asymptomatic infections remain undiagnosed and most diagnosed infections do not undergo antibiotic susceptibility testing, surveillance systems may underestimate the number of ceftriaxone non-susceptible infections. There is an urgent need for better interpretation and use of surveillance data to estimate the prevalence of resistance. In this modeling study, we simulated the spread of a new strain of ceftriaxone non-susceptible gonorrhea in a population of men who have sex with men as well as heterosexual men and women. We compared scenarios with varying strain characteristics and surveillance capacity. For each scenario, we estimated (i) the number of undetected infections by the time the non-susceptible strain was discovered and (ii) the likelihood of strain persistence in the absence of newly reported cases. Upon detection of one ceftriaxone non-susceptible isolate, the undetected disease burden was an estimated 5.4 infections with substantial uncertainty (0-18 infections, 95% uncertainty interval). In the absence of additional reports of ceftriaxone non-susceptible infections over the subsequent 180 days, the estimate declined to 2.5 infections with a narrower uncertainty interval (0-10 infections). The likelihood of ongoing transmission also declined from 66% (26-86%) at first detection to 2% (0-10%) after 180 days. Enhanced monitoring of the magnitude and trends of AMR is a key priority to reduce the burden of resistance and extend the useful lifespan of last-line antibiotics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the U.S. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA, #5 NU38PS004651). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC or other authors' affiliated institutions.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code and data are available at https://github.com/gradlab/iceberg.
